Factors influencing a second myeloid malignancy in patients with Philadelphia-negative -7 or del(7q) clones during tyrosine kinase inhibitor therapy for chronic myeloid leukemia

Cancer Genetics

Volumn 204, Issue 1, 2011, Pages 39-44

  Groves, Michael J ^a   Sales, Mark ^a   Baker, Lee ^a   Griffiths, Michael ^b   Pratt, Norman ^a   Tauro, Sudhir ^a  

^a UNIVERSITY OF DUNDEE   (United Kingdom)

^b BIRMINGHAM CHILDREN S HOSPITAL NHS FOUNDATION TRUST   (United Kingdom)

Author keywords

7; AML; CML; del(7q); MDS; Philadelphia negative; Tyrosine kinase inhibitor

Indexed keywords

DASATINIB; IMATINIB; NILOTINIB; PROTEIN TYROSINE KINASE INHIBITOR; ENZYME INHIBITOR; PROTEIN TYROSINE KINASE;

ACUTE GRANULOCYTIC LEUKEMIA; ADULT; AGED; ARTICLE; CANCER CHEMOTHERAPY; CANCER GROWTH; CANCER RISK; CHROMOSOME 7Q; CHROMOSOME DELETION; CHRONIC MYELOID LEUKEMIA; CLINICAL EVALUATION; CONTROLLED STUDY; DRUG EFFECT; DRUG RESPONSE; DRUG SUBSTITUTION; DRUG WITHDRAWAL; FOLLOW UP; GENETIC ASSOCIATION; HUMAN; KARYOTYPING; MAJOR CLINICAL STUDY; MALIGNANT TRANSFORMATION; MOLECULAR CLONING; MYELODYSPLASTIC SYNDROME; OUTCOME ASSESSMENT; PHILADELPHIA CHROMOSOME NEGATIVE CELL; PRIORITY JOURNAL; RISK ASSESSMENT; SECOND CANCER; SYSTEMATIC REVIEW; TREATMENT DURATION; CHROMOSOME 7; CYTOGENETICS; DRUG ANTAGONISM; FEMALE; GENETICS; MALE; MIDDLE AGED; PHILADELPHIA 1 CHROMOSOME; REGRESSION ANALYSIS; REPRODUCIBILITY; RISK;

ADULT; AGED; CHROMOSOMES, HUMAN, PAIR 7; CYTOGENETICS; ENZYME INHIBITORS; FEMALE; HUMANS; KARYOTYPING; LEUKEMIA, MYELOGENOUS, CHRONIC, BCR-ABL POSITIVE; MALE; MIDDLE AGED; NEOPLASMS, SECOND PRIMARY; PHILADELPHIA CHROMOSOME; PROTEIN-TYROSINE KINASES; REGRESSION ANALYSIS; REPRODUCIBILITY OF RESULTS; RISK;

EID: 79955650158     PISSN: 22107762     EISSN: 22107770     Source Type: Journal    
DOI: 10.1016/j.cancergencyto.2010.08.017     Document Type: Article

References (33)

1. Kantarjian HM, Cortes J, La Rosée P, et al. Optimizing therapy for patients with chronic myelogenous leukemia in chronic phase. Cancer 2010;116:1419-1430.
2. Goldman JM. How I treat chronic myeloid leukemia in the imatinib era. Blood 2007;110:2828e2837.
3. Baccarani M, Cortes J, Pane F, et al, European LeukemiaNet. Chronic myeloid leukemia: an update of concepts and management recommendations of European LeukemiaNet. J Clin Oncol 2009;27:6041-6051.
4. Goldman JM. Chronic myeloid leukemia: reversing the chronic phase. J Clin Oncol 2010;28:363e365.
5. Deininger MW, Cortes J, Paquette R, et al. The prognosis for patients with chronic myeloid leukaemia who have clonal cytogenetic abnormalities in Philadelphia chromosome-negative cells. Cancer 2007;110:1509-1519.
6. O'Dwyer ME, Gatter KM, Loriaux M, et al. Demonstration of Philadelphia chromosome negative abnormal clones in patients with chronic myelogenous leukemia during major cytogenetic responses induced by imatinib mesylate. Leukemia 2003;17: 481-487.
7. Terre C, Eclache V, Rousselot P, et al. Report of 34 patients with clonal chromosomal abnormalities in Philadelphia-negative cells during imatinib treatment of Philadelphia-positive chronic myeloid leukemia. Leukemia 2004;18:1340-1346.
8. Jabbour E, Kantarjian HM, Abruzzo LV, et al. Chromosomal abnormalities in Philadelphia chromosomeenegative metaphases appearing during imatinib mesylate therapy in patients with newly diagnosed chronic myeloid leukaemia in chronic phase. Blood 2007;110:2991-2995.
9. Lin Y, Bruyére H, Horsman DE, et al. Philadelphia-negative clonal hematopoiesis following imatinib therapy in patients with chronic myeloid leukaemia: a report of nine cases and analysis of predictive factors. Cancer Genet Cytogenet 2006;170:160-23.
10. Meeus P, Demuynck H, Martiat PH, et al. Sustained, clonal karyotype abnormalities in the Philadelphia chromosome negative cells of CML patients successfully treated with imatinib. Leukemia 2003;17:465-467.
11. O'Shea D, Crotty G, Carroll P, et al. Clonal karyotypic abnormalities in Philadelphia negative cells of CML patients treated with imatinib: is it under-reported and does it have any clinical significance? Br J Haematol 2004;127:367-369.
12. Bumm T, Müller C, Al-Ali HK, et al. Emergence of clonal cytogenetic abnormalities in Ph- cellsinsome CML patients in cytogenetic remission to imatinib but restoration of polyclonal hematopoiesis in the majority. Blood 2003;101:1941-1949.
13. Kovitz C, Kantarjian H, Garcia-Manero G, et al. Myelodysplastic syndromes and acute leukemia developing after imatinib mesylate therapy for chronic myeloid leukemia. Blood 2006;108: 2811-2813.
14. Abruzzese E, Gozzetti A, Galimberti S, et al. Characterization of Ph-negative abnormal clones emerging during imatinib therapy. Cancer 2007;109:2466-2472.
15. Perel JM, McCarthy C, Walker O, et al. Clinical significance of development of Philadelphia-chromosome negative clones in patients with chronic myeloid leukemia treated with imatinib mesylate. Haematologica 2005;90:e70-e71.
16. Athanasiadou A, Stavroyianni N, Saloum R, et al. Novel chromosomal aberrations in Philadelphia negative cells of chronic myelogenous leukemia patients on imatinib: report of three cases. Leukemia 2004;18:1029-1031.
17. Guilbert-Douet N, Morel F, Le Bris MJ, et al. Clonal chromosomal abnormalities in the Philadelphia chromosome negative cells of chronic myeloid leukaemia patients treated with imatinib. Leukemia 2004;18:1140-1142.
18. Andersen MK, Pedersen-Bjergaard J, Kjeldsen L, et al. Clonal Ph-negative hematopoiesis in CML after therapy with imatinib mesylate is frequently characterized by trisomy 8. Leukemia 2002;16:1390-1393.
19. Bacher U, Hochhaus A, Berger U, et al. Clonal aberrations in Philadelphia chromosome negative hematopoiesis in patients with chronic myeloid leukemia treated with imatinib or interferon alpha. Leukemia 2005;19:460-463.
20. Medina J, Kantarjian H, Talpaz M, et al. Chromosomal abnormalities in Philadelphia chromosome-negative metaphases appearing during imatinib mesylate therapy in patients with Philadelphia chromosome- positive chronic myelogenous leukemia in chronic phase. Cancer 2003;98:1905-1911.
21. Besalduch J, Guti Rrez A, Parody R, et al. Chromosomal abnormalities in Philadelphia (Ph)-negative cells of patients withchronic myeloide leukemia treated with Imatinib (ST1571). Haematologica 2003;88:e11-e12.
22. Herens C, Baron F, Croisiau C, et al. Clonal chromosome aberrations in Philadelphia-negative cells from chronic myelocytic leukemia patients treated with imatinib mesylate: report of two cases. Cancer Genet Cytogenet 2003;147:78-80.
23. McMullin MF, Humphreys M, Byrne J, et al. Chromosomal abnormalities in Ph- cells of patients on imatinib. Blood 2003; 102:2700-2701.
24. Espinet B, Oliveira AC, Boqué C, et al. Clonal cytogenetic abnormalities in patients with chronic myeloid leukemia in complete cytogenetic response to imatinib mesylate. Haematologica 2005;90:556-558.
25. Navarro JT, Feliu E, Grau J, et al. Monosomy 7 with severe myelodysplaia developing during imatinib treatment of Philadelphia-positive chronic myeloid leukaemia. Am J Hematol 2007;82:849-851.
26. Ross DM, Jackson SR, Browett PJ. Philadelphia-negative secondary acute myeloid leukaemia during imatinib treatment for chronic phase chronic myeloid leukaemia. Leuk Lymphoma 2007;48:1231-1233.
27. Zeidan A, Kakati S, Anderson B, et al. Monosomy 7 in t(9;22)-negative cells during nilotinib therapy in an imatinib-resistant chronic myeloid leukemia case. Cancer Genet Cytogenet 2007;176:169-171.
28. Conchon MR, Bendit I, Ferreira P, et al. Emergence of abnormal clone with monosomy 7 in Philadelphia negative cells of CML patients treated with tyrosine kinase inhibitors. Int J Haematol 2009;89:123-125.
29. Hackanson B, Rückert A, Lübbert M. Hyperleukocytotic secondary acute myeloid leukemia (AML) with sole monosomy 7 as sequela of Philadelphia-chromosome positive chronic myeloid leukemia (CML). Eur J Haematol 2009;83:611-612.
30. Larsson N, Billström R, Lilljebjörn H, et al. Genetic analysis of dasatinib-treated chronic myeloid leukemia rapidly developing into acute myeloid leukemia with monosomy 7 in Philadelphianegative cells. Cancer Genet Cytogenet 2010;199:89-95.
31. Hagemeijer A, Smit EM, Löwenberg B, et al. Chronic myeloid leukemia with permanent disappearance of the Ph1 chromosome and development of new clonal subpopulations. Blood 1979;53:1-14.
32. Fayad L, Kantarjian H, O'Brien S, et al. Emergence of new clonal abnormalities following interferon-alpha induced complete cytogenetic response in patients with chronic myeloid leukemia: report of three cases. Leukemia 1997;11:767-771.
33. Ariyama T, Inazawa J, Uemura Y, et al. Clonal origin of Philadelphia chromosome negative cells with trisomy 8 appearing during the course of alpha-interferon therapy for Ph positive chronic myelocytic leukemia. Cancer Genet Cytogenet 1995;81: 20-23.